Academic Journal

Macromolecular design of a bivalirudin peptide-loaded Carbopol 940 hydrogel for local thrombin inhibition and prevention of neointimal hyperplasia.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Macromolecular design of a bivalirudin peptide-loaded Carbopol 940 hydrogel for local thrombin inhibition and prevention of neointimal hyperplasia.
Συγγραφείς: Huang TY; Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617, Taiwan; Division of Thoracic & Cardiovascular Surgery, Chang Gung Memorial Hospital at Keelung, 222 Mai-Chin Road, Keelung, 204, Taiwan. Electronic address: d07528011@gmail.com., Chiu WC; Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617, Taiwan., Liang YJ; Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617, Taiwan., Chen PY; Department of Neurosurgery, Chang Gung Memorial Hospital at Keelung, 222 Mai-Chin Road, Keelung, 204, Taiwan; School of Medicine, Chang Gung University, No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City, 33302, Taiwan., Wang YC; Division of Thoracic & Cardiovascular Surgery, Chang Gung Memorial Hospital at Keelung, 222 Mai-Chin Road, Keelung, 204, Taiwan., Lin FH; Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617, Taiwan; National Health Research Institutes, 35, Keyan Road, Zhunan Town, Miaoli County, 350, Taiwan.
Πηγή: International journal of biological macromolecules [Int J Biol Macromol] 2026 Sep; Vol. 374, pp. 153323. Date of Electronic Publication: 2026 Jul 01.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE
Imprint Name(s): Publication: Amsterdam : Elsevier
Original Publication: Guildford, Eng., IPC Science and Technology Press.
Ιατρικοί όροι (MeSH): Hirudins*/chemistry , Hirudins*/pharmacology , Peptide Fragments*/chemistry , Peptide Fragments*/pharmacology , Hydrogels*/chemistry , Acrylic Resins*/chemistry , Neointima*/drug therapy , Neointima*/pathology , Neointima*/prevention & control , Neointima*/metabolism , Hyperplasia*/prevention & control , Thrombin*/antagonists & inhibitors , Thrombin*/metabolism , Antithrombins*/chemistry , Antithrombins*/pharmacology, Recombinant Proteins/chemistry ; Recombinant Proteins/pharmacology ; Cell Proliferation/drug effects ; Animals ; Humans ; Rats ; Male ; Drug Liberation ; Rats, Sprague-Dawley ; Cell Line
Περίληψη: Neointimal hyperplasia (NIH) at vascular anastomosis sites remains a significant cause of graft failure after cardiovascular surgery. Here, we developed a bivalirudin-incorporated Carbopol 940 hydrogel (C-Biv) that provides sustained local thrombin inhibition, thereby preventing early thrombosis and subsequent smooth muscle proliferation. Bivalirudin is a 20-amino-acid thrombin-inhibiting peptide, and C-Biv was designed as a macromolecular network to modulate its local release and bioactivity at vascular anastomosis sites. Carbopol 940, a crosslinked polyacrylic acid, was selected for its high viscosity, pH-sensitive swelling, and established biocompatibility as a macromolecular carrier. Rheological characterization identified 0.5% (w/v) Carbopol 940 as the optimal formulation, achieving a viscosity comparable to that of medical lubricating gels (approximately 150 Pa·s). Drug-release analysis showed an initial burst of 60% bivalirudin within 24 h, followed by gradual release up to 72 h. The hydrogel exhibited excellent cytocompatibility (>90% cell viability in L929, A7r5, and HUVECs) and no measurable cytotoxicity as assessed by live/dead staining. In a rat abdominal aortic repair model, C-Biv application significantly reduced arterial wall thickening (showing a trend at 4 weeks: 373.4% in the PR group vs 152.6% in the C-Biv group, p = 0.0854; and a significant reduction at 12 weeks: 262.8% vs 126.9%, p = 0.0456) and decreased PCNA- and α-SMA-positive cell accumulation by over 40% at 4 and 12 weeks, without altering systemic biochemical parameters. These findings indicate that local delivery of bivalirudin via a biocompatible Carbopol 940 matrix effectively suppresses thrombin-mediated vascular remodeling, providing a practical and safe strategy for preventing postoperative vascular stenosis.
(Copyright © 2026 The Authors. Published by Elsevier B.V. All rights reserved.)
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
Contributed Indexing: Keywords: Carbopol 940 hydrogel; bivalirudin peptide; neointimal hyperplasia
Substance Nomenclature: 0 (Hirudins)
TN9BEX005G (bivalirudin)
0 (Peptide Fragments)
0 (Recombinant Proteins)
0 (Hydrogels)
0 (Acrylic Resins)
4Q93RCW27E (carbopol 940)
EC 3.4.21.5 (Thrombin)
0 (Antithrombins)
Entry Date(s): Date Created: 20260701 Date Completed: 20260821 Latest Revision: 20260821
Update Code: 20260821
DOI: 10.1016/j.ijbiomac.2026.153323
PMID: 42385809
Βάση Δεδομένων: MEDLINE